GeneDx Revenue Soars 46% on Diagnostic Demand, Fabric Genomics Boost

TL;DR

**GeneDx is burning less cash and growing revenue fast, but they're still losing money – watch for profitability, not just top-line growth.**

AI Summary

GeneDx Holdings Corp. reported a significant increase in diagnostic test revenue, reaching $113.523 million for the three months ended September 30, 2025, up from $77.418 million in the prior year period, representing a 46.6% increase. Total revenue for the quarter was $116.743 million, compared to $76.874 million in Q3 2024. Despite revenue growth, the company posted a net loss of $7.635 million for the quarter, a slight improvement from a net loss of $8.312 million in Q3 2024. For the nine months ended September 30, 2025, net loss significantly improved to $3.355 million from $57.724 million in the same period last year. Key business changes include the acquisition of Fabric Genomics, Inc. on May 5, 2025, which added $12.798 million in goodwill and $172.585 million in intangible assets to the balance sheet. The company's cash and cash equivalents increased to $95.968 million as of September 30, 2025, from $85.212 million at December 31, 2024, partly due to $25.568 million in proceeds from ATM offerings. Risks include the company ceasing to qualify as an emerging growth company by December 31, 2025, which will increase reporting requirements, and ongoing losses, though significantly reduced. The strategic outlook focuses on leveraging genomic expertise and data science, particularly through the Fabric Genomics acquisition, to enhance personalized medical care and accelerate drug discovery.

Why It Matters

GeneDx's substantial revenue growth, driven by diagnostic testing and the Fabric Genomics acquisition, signals strong market demand for genomic diagnostics, potentially positioning it as a leader in personalized medicine. For investors, the reduced net loss and increased cash reserves, despite ongoing losses, suggest improving financial health and operational efficiency. Employees at GeneDx and Fabric Genomics will see continued investment in their combined expertise, while customers can expect enhanced genomic interpretation capabilities. In the broader market, this move intensifies competition in the rapidly evolving genomics sector, pushing rivals to innovate in data science and diagnostic accuracy.

Risk Assessment

Risk Level: medium — The company reported a net loss of $7.635 million for the three months ended September 30, 2025, and an accumulated deficit of $1.355 billion, indicating continued unprofitability. While cash and cash equivalents increased to $95.968 million, the company will cease to qualify as an 'emerging growth company' by December 31, 2025, which will increase compliance costs and reporting burdens.

Analyst Insight

Investors should monitor GeneDx's path to profitability, specifically looking for continued reduction in net losses and positive operating cash flow in future reports. The significant revenue growth is positive, but sustained losses and increased compliance costs post-EGC status warrant caution. Consider the long-term potential of the Fabric Genomics acquisition to drive future earnings.

Financial Highlights

debt To Equity

0.69

revenue

$116.743M

operating Margin

-2.8%

total Assets

$493.902M

total Debt

$108.732M

net Income

$(7.635M)

eps

N/A

gross Margin

72.4%

cash Position

$95.968M

revenue Growth

+51.8%

Revenue Breakdown

Key Numbers

• $113.523M — Diagnostic Test Revenue (Q3 2025) (Increased 46.6% from $77.418M in Q3 2024)
• $116.743M — Total Revenue (Q3 2025) (Up from $76.874M in Q3 2024)
• $(7.635M) — Net Loss (Q3 2025) (Improved from $(8.312M) in Q3 2024)
• $(3.355M) — Net Loss (YTD Sep 2025) (Significantly improved from $(57.724M) in YTD Sep 2024)
• $95.968M — Cash and Cash Equivalents (Increased from $85.212M at Dec 31, 2024)
• $12.798M — Goodwill (Resulting from Fabric Genomics acquisition)
• $172.585M — Intangible Assets, net (Increased from $158.600M at Dec 31, 2024, due to Fabric Genomics acquisition)
• $25.568M — Proceeds from ATM offering (YTD Sep 2025) (Contributed to increased cash)
• 28,889,689 — Class A Common Stock Outstanding (As of September 30, 2025)
• $(0.12) — Basic and Diluted Loss Per Share (YTD Sep 2025) (Improved from $(2.17) in YTD Sep 2024)

Key Players & Entities

• GeneDx Holdings Corp. (company) — registrant
• Fabric Genomics, Inc. (company) — acquired company
• SEC (regulator) — Securities and Exchange Commission
• $113.523 million (dollar_amount) — diagnostic test revenue for Q3 2025
• $7.635 million (dollar_amount) — net loss for Q3 2025
• $3.355 million (dollar_amount) — net loss for nine months ended September 30, 2025
• $95.968 million (dollar_amount) — cash and cash equivalents as of September 30, 2025
• $12.798 million (dollar_amount) — goodwill from Fabric Genomics acquisition
• $172.585 million (dollar_amount) — intangible assets from Fabric Genomics acquisition
• Jumpstart Our Business Startups Act of 2012 (regulator) — JOBS Act

FAQ

Risk Factors

• Loss of Emerging Growth Company Status [medium — regulatory]: The company may cease to qualify as an emerging growth company by December 31, 2025. This will trigger increased reporting requirements, potentially increasing compliance costs and administrative burden.
• Ongoing Net Losses [medium — financial]: Despite significant improvement, the company reported a net loss of $7.635 million for Q3 2025 and $3.355 million year-to-date. Continued losses could impact future funding and operational flexibility.
• Integration of Fabric Genomics [medium — operational]: The acquisition of Fabric Genomics, Inc. on May 5, 2025, added substantial goodwill ($12.798 million) and intangible assets ($172.585 million). Successful integration is crucial for realizing the strategic benefits and avoiding potential impairment charges.
• Dependence on ATM Offerings [low — financial]: The company raised $25.568 million through ATM offerings year-to-date, contributing to its cash position. Over-reliance on such offerings could dilute existing shareholders and may not be sustainable long-term.

Industry Context

The diagnostics and genomics sector is characterized by rapid technological advancement and increasing demand for personalized medicine. GeneDx operates in a competitive landscape with players focusing on genetic testing, data analytics, and drug discovery support. Key trends include the integration of AI and machine learning for data interpretation and the expansion of genomic sequencing services.

Regulatory Implications

The company faces potential increased scrutiny and reporting obligations if it loses its Emerging Growth Company status by the end of 2025. This transition will require adherence to stricter SEC regulations, impacting compliance costs and disclosure requirements.

What Investors Should Do

1. Monitor the impact of the Fabric Genomics acquisition
2. Evaluate the path to profitability
3. Track regulatory compliance costs

Key Dates

• 2025-09-30: End of Q3 2025 — Reported strong diagnostic test revenue growth of 46.6% and significant improvement in year-to-date net loss.
• 2025-05-05: Acquisition of Fabric Genomics, Inc. — Materially impacted the balance sheet with $12.798M in goodwill and $172.585M in intangible assets, aiming to enhance genomic expertise and data science capabilities.
• 2025-12-31: Potential loss of Emerging Growth Company status — Marks a critical deadline for increased regulatory and reporting requirements, impacting operational costs and compliance.

Glossary

Goodwill

An intangible asset that arises when one company acquires another for a price greater than the fair market value of its identifiable net assets. (Represents the premium paid for the acquisition of Fabric Genomics, Inc., indicating expected future economic benefits.)

Intangible assets, net

Non-physical assets that have value, such as patents, copyrights, and brand names. 'Net' implies accumulated amortization has been deducted. (Significantly increased due to the Fabric Genomics acquisition, reflecting the value of its technology and intellectual property.)

ATM offerings

At-the-market offerings, where a company sells shares of its stock on public exchanges at prevailing market prices. (A source of capital for the company, as evidenced by the $25.568 million raised year-to-date, contributing to cash reserves.)

Accumulated deficit

The cumulative net losses of a company since its inception, less any net profits. (Indicates the company has historically operated at a loss, though the deficit has narrowed significantly in the current year.)

Year-Over-Year Comparison

GeneDx Holdings Corp. has demonstrated robust revenue growth, with total revenue increasing by approximately 51.8% year-over-year for the nine months ended September 30, 2025. Diagnostic test revenue, in particular, saw a substantial 46.6% jump in Q3 2025 compared to the prior year. While the company has significantly reduced its net loss from $57.724 million to $3.355 million year-to-date, it continues to operate at a loss. The balance sheet reflects the impact of the Fabric Genomics acquisition, with notable increases in goodwill and intangible assets. Cash position has improved, partly due to ATM offerings, but the company faces potential increased regulatory burdens.

Key Financial Figures

• $0.0001 — stered Class A common stock, par value $0.0001 per share WGS The Nasdaq Stock Market L
• $379.50 — mon stock, each at an exercise price of $379.50 per share WGSWW The Nasdaq Stock Market
• $0 — ares of Class A common stock, par value $0.0001, outstanding at October 24, 2025.

Filing Documents

• wgs-20250930.htm (10-Q) — 1382KB
• exhibit311-ceocertificatio.htm (EX-31.1) — 10KB
• exhibit312-cfocertificatio.htm (EX-31.2) — 10KB
• exhibit321-ceocertificatio.htm (EX-32.1) — 5KB
• exhibit322-cfocertificatio.htm (EX-32.2) — 5KB
• wgs-20250930_g1.jpg (GRAPHIC) — 16KB
• 0001818331-25-000130.txt ( ) — 8639KB
• wgs-20250930.xsd (EX-101.SCH) — 54KB
• wgs-20250930_cal.xml (EX-101.CAL) — 89KB
• wgs-20250930_def.xml (EX-101.DEF) — 371KB
• wgs-20250930_lab.xml (EX-101.LAB) — 756KB
• wgs-20250930_pre.xml (EX-101.PRE) — 562KB
• wgs-20250930_htm.xml (XML) — 1282KB

Financial Information

Part I. Financial Information Item 1. Condensed Consolidated Financial Statements (Unaudited) 4 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 26 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 35 Item 4.

Controls and Procedures

Controls and Procedures 35

Other Information

Part II. Other Information Item 1.

Legal Proceedings

Legal Proceedings 36 Item 1A.

Risk Factors

Risk Factors 36 Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities 37 Item 3. Defaults Upon Senior Securities 37 Item 4. Mine Safety Disclosures 37 Item 5. Other Information 37 Item 6. Exhibits 41

Signatures

Signatures 42 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Certain matters discussed in this report, including matters discussed under the caption "Management's Discussion and Analysis of Financial Condition and Results of Operations," may constitute forward-looking statements for purposes of the Securities Act of 1933, as amended (the "Securities Act"), and the Securities Exchange Act of 1934, as amended, (the "Exchange Act"), and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from the future results, performance or achievements expressed or implied by such forward-looking statements. The words "anticipate," "believe," "estimate," "may," "expect" and similar expressions are generally intended to identify forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation, those discussed under the captions "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in this report, as well as other factors which may be identified from time to time in our other filings with the Securities and Exchange Commission (the "SEC"), or in the documents where such forward-looking statements appear. All written or oral forward-looking statements attributable to us are expressly qualified in their entirety by these cautionary statements. Such forward-looking statements include, but are not limited to, statements about: our estimates of the sufficiency of our existing capital resources combined with future anticipated cash flows and future capital requirements to finance our operating requirements, and capital expenditures; our expectations for generating revenue, incurring losses, and remaining profitable on a sustained basis; unforeseen circumstances or other disruptions to no

- Financial Information

Part I - Financial Information

Condensed Consolidated Financial Statements

Item 1. Condensed Consolidated Financial Statements GeneDx Holdings Corp. Condensed Consolidated Balance Sheets (in thousands, except share and per share amounts) September 30, 2025 (Unaudited) December 31, 2024 Assets: Current assets: Cash and cash equivalents $ 95,968 $ 85,212 Marketable securities 59,111 55,973 Accounts receivable 60,938 37,629 Inventory, net 10,569 10,650 Prepaid expenses and other current assets 10,997 8,504 Total current assets 237,583 197,968 Operating lease right-of-use assets 24,200 25,613 Property and equipment, net 42,422 32,893 Goodwill 12,798 — Intangible assets, net 172,585 158,600 Other assets 4,314 4,306 Total assets $ 493,902 $ 419,380 Liabilities and Stockholders' Equity: Current liabilities: Accounts payable and accrued expenses $ 50,334 $ 30,983 Short-term lease liabilities 4,429 3,336 Other current liabilities 32,858 20,498 Total current liabilities 87,621 54,817 Long-term debt, net of current portion 51,579 51,913 Long-term lease liabilities 57,153 60,919 Other liabilities 4,258 5,519 Deferred taxes 1,033 965 Total liabilities 201,644 174,133 Purchase commitments and contingencies (Note 10) Stockholders' Equity: Preferred Stock, $ 0.0001 par value: 1,000,000 shares authorized, 0 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively — — Class A common stock, $ 0.0001 par value: 1,000,000,000 shares authorized, 28,889,689 and 28,016,545 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 2 2 Additional paid-in capital 1,647,083 1,596,889 Accumulated deficit ( 1,355,829 ) ( 1,352,474 ) Accumulated other comprehensive income 1,002 830 Total stockholders' equity 292,258 245,247 Total liabilities and stockholders' equity $ 493,902 $ 419,380 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 4 Table of Contents GeneDx Holdings Corp. Condensed Consolidated Sta

View Full Filing

View this 10-Q filing on SEC EDGAR